The Hepatitis B Foundation is an official charity partner of the TCS New York City Marathon. Support our #Run4HepB team, donate today!

News Archive

News Archive

Cancer survivors: Managing your emotions after cancer treatment

Researchers Identify a New tsRNA in Blood to Improve Liver Cancer Diagnosis

Case 3: Novel Frontline Combination Strategies for Unresectable HCC (Video)

Antiviral therapy improves survival among elderly patients after hepatectomy for hepatitis B virus (HBV)–related hepatocellular carcinoma (HCC)

AstraZeneca’s immunotherapy tremelimumab has secured its first FDA approval and is to be sold under the brand name Imjudo

FDA approves a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with unresectable hepatocellular cancer, the most common type of liver cancer

Evidence Grows for Avoiding Biopsy in Hepatocellular Carcinoma

New Guidelines Clarify Use of Systemic Therapy in Advanced HCC

ASTRO Issues Clinical Guideline on External Beam Radiation Therapy for Primary Liver Cancers

After FDA Evaluation, BMS Withdraws Opdivo For Liver Cancer Treatment in Patients Previously Treated with Sorafenib in the U.S.

FDA Grants “Orphan Drug” Designation to Chemotherapeutic Uttroside-B for Use in Patients with HCC. The drug is in pre-clinical testing.

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline

COVID-19: What People With Cancer Need to Know (, June 2020)

FDA Approves Atezolizumab Plus Bevacizumab for Patients With Unresectable or Metastatic Hepatocellular Carcinoma 

Atezolizumab Combination Improves Survival in HCC (Cancer Letter, May 2020)

U.S. FDA Approves Opdivo® (Nivolumab) + Yervoy® (Ipilimumab) for Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

U.S. Food and Drug Administration (FDA) Has Granted Breakthrough Device Designation to the Elecsys® GALAD Score to Help Diagnose HCC

FDA Has Approved Cabozantinib (CABOMETYX, Exelixis, Inc.) for Patients with Hepatocellular Carcinoma Who Have Been Previously Treated with Sorafenib

DNA Search Finds People Resistant to Liver Disease. Can We Mimic This Effect with a Drug? Regeneron and Alnylam Pharmaceutical to Partner  

Newly Discovered Anti-Cancer Protein LHPP Prevents Uncontrolled Proliferation of Cancer Cells in the Liver and May Serve as a Biomarker for the Diagnosis & Prognosis of Liver Cancer 

New Point-of-Care Ultrasound Tool May Aid Detection of Liver Stiffness in Obese Patients

Phase II Trial of GT90001 Plus Nivolumab Enrolls First Patient with Advanced HCC

Treatment of Hepatocellular Carcinoma in Sub-Saharan Africa: Challenges and Solutions

Kintor Initiates Dosing in Phase II Hepatocellular Carcinoma Therapy Trial

How Have Hepatocellular Carcinoma Treatments Improved?

Neoadjuvant Immunotherapy for Resectable Hepatocellular Carcinoma

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of HCC

Perioperative Opdivo Alone, in Combination with Yervoy, Safe for Patients with HCC

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

AACR Report Finds Racial and Ethnic Minorities Continue to Shoulder a Disproportionate Burden of Cancer

Cabozantinib Plus Atezolizumab in Advanced Hepatocellular Carcinoma and the Role of Adjuvant Antiviral Therapy

Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma

Elevar Therapeutics and Hengrui Pharma Announce Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival in Patients With Unresectable Hepatocellular Carcinoma (Phase III Trial)

New Study Shows Options for Older Patients With Liver Cancer

Novartis and BeiGene have announced new data from a phase 3 trial that shows tislelizumab demonstrated non-inferior overall survival (OS) compared to sorafenib in patients with previously untreated, unresectable hepatocellular carcinoma

Dr Reddy’s Laboratories announces the launch of Dr Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the US market following the approval by the US Food and Drug Administration

JW Therapeutics announces the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma

The International Liver Cancer Network (ILCN), of which HBF is a member, released a white paper promoting increased effort to improve prevention, early detection and access to care for liver cancer.

Cancer Burden Facing Asian Americans Partly Caused By Racism